Biden Budget Gives Drug Pricing Reform A Spotlight But No Specifics
Approach leaves policy development to Congress. The President understands the need to build consensus around specific policies to achieve his goals, White House Office of Management and Budget Acting Director Shalanda Young explains.
You may also be interested in...
White House confirms that it will not be pushing major drug pricing provisions to help pay for its next multi-trillion dollar legislative proposal. That sounds like good news for industry – but don’t pop the champagne just yet.
In the report accompanying FY 2023 HHS appropriations legislation, the House committee also addresses biosimilar uptake in Part D, Medicare dispensing fees for oral COVID-19 drugs and NIH grants for expanded access to investigational ALS drugs.
US legislation attempts to address manufacturer, pharmacy benefit manager impact on patient costs in addition to health plan benefit designs. Critics suggest it’s too easy on manufacturers but that may help its chances with Republicans.